Morrison Jonathan J, Galgon Richard E, Jansen Jan O, Cannon Jeremy W, Rasmussen Todd E, Eliason Jonathan L
J Trauma Acute Care Surg. 2016 Feb;80(2):324-34. doi: 10.1097/TA.0000000000000913.
Torso hemorrhage remains a leading cause of potentially preventable death within trauma, acute care, vascular, and obstetric practice. A proportion of patients exsanguinate before hemorrhage control. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is an adjunct designed to sustain the circulation until definitive hemostasis. A systematic review was conducted to characterize the current clinical use of REBOA and its effect on hemodynamic profile and mortality.
A systematic review (1946-2015) was conducted using EMBASE and MEDLINE. Original studies on human subjects, published in English language journals, were considered. Articles were included if they reported data on hemodynamic profile and mortality.
A total of 83 studies were identified; 41 met criteria for inclusion. Clinical settings included postpartum hemorrhage (5), upper gastrointestinal bleeding (3), pelvic surgery (8), trauma (15), and ruptured aortic aneurysm (10). Of the 857 patients, overall mortality was 423 (49.4%); shock was evident in 643 (75.0%). Pooled analysis demonstrated an increase in mean systolic pressure by 53 mm Hg (95% confidence interval, 44-61 mm Hg) following REBOA use. Data exhibited moderate heterogeneity with an I of 35.5.
REBOA has been used in a variety of clinical settings to successfully elevate central blood pressure in the setting of shock. Overall, the evidence base is weak with no clear reduction in hemorrhage-related mortality demonstrated. Formal, prospective study is warranted to clarify the role of this adjunct in torso hemorrhage.
Systematic review, level IV.
躯干出血仍然是创伤、急性护理、血管和产科医疗中潜在可预防死亡的主要原因。一部分患者在出血得到控制之前就会因失血过多而死亡。复苏性血管内主动脉球囊阻断术(REBOA)是一种辅助手段,旨在维持循环直至实现确切止血。本研究进行了一项系统评价,以描述REBOA目前的临床应用情况及其对血流动力学特征和死亡率的影响。
使用EMBASE和MEDLINE进行了一项系统评价(1946 - 2015年)。纳入了发表在英文期刊上的关于人类受试者的原始研究。如果文章报告了血流动力学特征和死亡率的数据,则予以纳入。
共识别出83项研究;41项符合纳入标准。临床情况包括产后出血(5例)、上消化道出血(3例)、盆腔手术(8例)、创伤(15例)和主动脉瘤破裂(10例)。在857例患者中,总体死亡率为423例(49.4%);643例(75.0%)出现休克。汇总分析表明,使用REBOA后平均收缩压升高了53 mmHg(95%置信区间,44 - 61 mmHg)。数据显示存在中度异质性,I²为35.5。
REBOA已在多种临床情况下用于在休克状态下成功升高中心血压。总体而言,证据基础薄弱,未显示出与出血相关的死亡率有明显降低。有必要进行正式的前瞻性研究以阐明这种辅助手段在躯干出血中的作用。
系统评价,IV级。